AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25298577 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OZP)
Number of subjects: 64
Study 25298577 — intervention group
Group type: COMPARATOR
Intervention: Comparison between RSP and OZP
Number of subjects: 64
Study 22001689 — intervention group
Group type: EXPERIMENTAL
Intervention: Written materials and basic Web access (RCT1)
Number of subjects: 1755
Study 22001689 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Web site (RCT2)
Number of subjects: 1755
Study 22001689 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief telephone/e‐mail coaching support (RCT3)
Number of subjects: 1755
Study 21516922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 1% (LIDO)
Number of subjects: 60
Study 21516922 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline with preservatives (NSP)
Number of subjects: 60
Study 21516922 — intervention group
Group type: COMPARATOR
Intervention: Normal saline without preservatives (NS)
Number of subjects: 60
Study 17268258 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace intervention
Number of subjects: 196
Study 17268258 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded activity
Number of subjects: 196
Study 17268258 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 196
Study 17268258 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 196
Study 16136947 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Xin Mai Tong (XMT) capsules
Number of subjects: 0
Study 16136947 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12189365 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg to 40 mg once daily)
Number of subjects: 21
Study 10338353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofric catheter
Number of subjects: 20
Study 10338353 — intervention group
Group type: COMPARATOR
Intervention: EasiCath catheter
Number of subjects: 20
Study 8750400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg twice daily for 3 days
Number of subjects: 81
Study 8750400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 1780419 — intervention group
Group type: EXPERIMENTAL
Intervention: Light inhaling smokers
Number of subjects: 0
Study 1780419 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep inhaling smokers
Number of subjects: 0
Study 1780419 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking subjects (controls)
Number of subjects: 0
Study 6110654 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate added to neuroleptic treatment
Number of subjects: 18
Study 6110654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30657056 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (specific training in safety, incident recording over 15 days, feedback on performance)
Number of subjects: 138
Study 30657056 — intervention group
Group type: COMPARATOR
Intervention: Control group (no action taken)
Number of subjects: 138
Study 28978543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream cheese
Number of subjects: 43
Study 28978543 — intervention group
Group type: COMPARATOR
Intervention: Butter (control)
Number of subjects: 43
Study 28978543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheddar cheese
Number of subjects: 43
Study 27852706 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (BoNT‐A) injection guided by electrostimulation
Number of subjects: 30
Study 27852706 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (BoNT‐A) injection guided by ultrasound
Number of subjects: 30
Study 24468886 — intervention group
Group type: EXPERIMENTAL
Intervention: GCPGC at 100 μg/kg
Number of subjects: 25
Study 24468886 — intervention group
Group type: EXPERIMENTAL
Intervention: GCPGC at 30-100 μg/kg
Number of subjects: 25
Study 24468886 — intervention group
Group type: EXPERIMENTAL
Intervention: GCPGC at 300 μg/kg
Number of subjects: 25
Study 24468886 — intervention group
Group type: COMPARATOR
Intervention: Pegfilgrastim at 100 μg/kg
Number of subjects: 25
Study 22081256 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel tapering (75 mg every other day for 4 weeks)
Number of subjects: 20
Study 22081256 — intervention group
Group type: COMPARATOR
Intervention: Abrupt cessation of clopidogrel (Off group)
Number of subjects: 20
Study 20853929 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention delivered by counselors
Number of subjects: 2151
Study 18065578 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily fish (salmon and albacore tuna) - 2 servings per week
Number of subjects: 22
Study 18065578 — intervention group
Group type: COMPARATOR
Intervention: Fish-oil capsules - 1-2 capsules per day
Number of subjects: 22
Study 16617852 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (MMU-simulator with additional strain in the second interval)
Number of subjects: 23
Study 16617852 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (MMU-simulator with additional strain in the first interval)
Number of subjects: 23
Study 16617852 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (blood sampling for hormone analysis)
Number of subjects: 23
Study 16617852 — intervention group
Group type: COMPARATOR
Intervention: Group 1 and Group 2 (comparison of strain vs rest)
Number of subjects: 23
Study 12412493 — intervention group
Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 0
Study 12412493 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior experience
Number of subjects: 0
Study 12412493 — intervention group
Group type: COMPARATOR
Intervention: No training or prior experience
Number of subjects: 0
Study 10217331 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (10 microg/kg)
Number of subjects: 8
Study 10217331 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (5 microg/kg)
Number of subjects: 8
Study 10217331 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (5 microg/kg)
Number of subjects: 8
Study 10217331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8688981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg t.i.d.)
Number of subjects: 10
Study 8688981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1318083 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (100 micrograms IV)
Number of subjects: 19
Study 1318083 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 healthy men)
Number of subjects: 19
Study 6496286 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (453 ± 75 mg per day) + Isosorbide dinitrate (117 ± 63 mg per day)
Number of subjects: 9
Study 6496286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (71 ± 14 mg per day) + Isosorbide dinitrate (117 ± 63 mg per day)
Number of subjects: 9
Study 6496286 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (117 ± 63 mg per day) alone
Number of subjects: 9
Study 31004135 — intervention group
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS) with ferrous fumarate (FeFum) in water
Number of subjects: 34
Study 31004135 — intervention group
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS) with ferrous fumarate (FeFum) in a test meal
Number of subjects: 34
Study 31004135 — intervention group
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS) with ferrous fumarate (FeFum) in a test meal after 4 weeks of GOS consumption
Number of subjects: 34
Study 31004135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (FeSO4) in a test meal with GOS after 4 weeks of GOS consumption
Number of subjects: 34
Study 31004135 — intervention group
Group type: COMPARATOR
Intervention: Ferrous fumarate (FeFum) in a test meal without GOS after 4 weeks of GOS consumption
Number of subjects: 34
Study 29902299 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual HER2-targeted therapy (lapatinib and trastuzumab)
Number of subjects: 245
Study 27357281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) neopterin levels in delirium patients (median 29.6 nmol/mL)
Number of subjects: 139
Study 27357281 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum neopterin levels in delirium patients (median 37.0 nmol/mL)
Number of subjects: 139
Study 27357281 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF neopterin levels
Number of subjects: 139
Study 27357281 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher neopterin levels (CSF and serum)
Number of subjects: 139
Study 26179185 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary NO3 (‐) from beetroot juice (11.2 mmol)
Number of subjects: 9
Study 22999380 — intervention group
Group type: EXPERIMENTAL
Intervention: CRA plus vouchers program
Number of subjects: 118
Study 22999380 — intervention group
Group type: COMPARATOR
Intervention: Community reinforcement approach (CRA) treatment
Number of subjects: 118
Study 20459475 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) - 572.8 mg tea catechins (TC) daily
Number of subjects: 12
Study 20459475 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) - 0 mg tea catechins (TC) daily
Number of subjects: 12
Study 18946457 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation of five micronutrients (vitamin A, vitamin C, vitamin E, folic acid, and zinc)
Number of subjects: 800
Study 18946457 — intervention group
Group type: EXPERIMENTAL
Intervention: Single micronutrient supplementation (in sub-groups)
Number of subjects: 800
Study 18946457 — intervention group
Group type: COMPARATOR
Intervention: Control group (no micronutrient supplementation)
Number of subjects: 800
Study 16820802 — intervention group
Group type: COMPARATOR
Intervention: Standard sodium fluoride dentifrice (treatment period 1)
Number of subjects: 16
Study 16820802 — intervention group
Group type: COMPARATOR
Intervention: Standard sodium fluoride dentifrice (treatment period 2)
Number of subjects: 16
Study 16820802 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial stannous fluoride/sodium hexametaphosphate dentifrice (treatment period 3)
Number of subjects: 16
Study 14617230 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 70 (Dinner70 regimen)
Number of subjects: 16
Study 14617230 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 50 (Dinner50 regimen)
Number of subjects: 16
Study 10763941 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg q.a.m.
Number of subjects: 376
Study 10763941 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 376
Study 9149895 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Frequency Questionnaire (FFQ) screening for dietary eligibility
Number of subjects: 183
Study 9149895 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised criteria for FFQ screening
Number of subjects: 183
Study 9149895 — intervention group
Group type: EXPERIMENTAL
Intervention: Target calcium and dietary fiber values
Number of subjects: 183
Study 8429120 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR alpha-tocopherol
Number of subjects: 12
Study 3119287 — intervention group
Group type: EXPERIMENTAL
Intervention: Two silastic rods (Norplant)
Number of subjects: 250
Study 3119287 — intervention group
Group type: COMPARATOR
Intervention: Six capsules (Norplant)
Number of subjects: 250
Study 30305280 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (200 mg/d, max 300 mg/d for East Asians) plus azacitidine (75 mg/m2 subcutaneously once daily for 7 days every 28 days)
Number of subjects: 356
Study 30305280 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus azacitidine (75 mg/m2 subcutaneously once daily for 7 days every 28 days)
Number of subjects: 356
Study 30305280 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag plus azacitidine
Number of subjects: 356
Study 30305280 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus azacitidine
Number of subjects: 356
Study 26528941 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate (0.02 mg/kg)
Number of subjects: 5
Study 26528941 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 5
Study 25180479 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoenergetic diet rich in ALA (3.4 g/d)
Number of subjects: 81
Study 25180479 — intervention group
Group type: COMPARATOR
Intervention: Hypoenergetic diet low in ALA (0.9 g/d, control)
Number of subjects: 81
Study 22857017 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated, interactive telephone-delivered management intervention (TLC Diabetes)
Number of subjects: 120
Study 22857017 — intervention group
Group type: COMPARATOR
Intervention: Usual routine care
Number of subjects: 120
Study 21169251 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib added to gemcitabine
Number of subjects: 0
Study 21169251 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 0
Study 21169251 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study 17611913 — intervention group
Group type: COMPARATOR
Intervention: Conventional chromoendoscopy with acetic acid (CAA)
Number of subjects: 57
Study 17611913 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed virtual chromoendoscopy (CVC)
Number of subjects: 57
Study 16037757 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vaginal estrogen therapy (ET group)
Number of subjects: 56
Study 12400824 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron beam coronary angiography
Number of subjects: 27
Study 8049820 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (1,000 IU/d), Calcium (1 g/d), EHDP (7.5 mg/kg body weight)
Number of subjects: 33
Study 8049820 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 33
Study 2838923 — intervention group
Group type: EXPERIMENTAL
Intervention: Kabi 2165 (2,500 anti-Xa units once daily)
Number of subjects: 385
Study 2838923 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin (5,000 IU twice daily)
Number of subjects: 385
Study 2838923 — intervention group
Group type: EXPERIMENTAL
Intervention: Kabi 2165
Number of subjects: 385
Study 31786983 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone 2.5 mg/day
Number of subjects: 1001
Study 31786983 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone 5 mg/day
Number of subjects: 1001
Study 31786983 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone 50 mg/day
Number of subjects: 1001
Study 30969910 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditec version of NU-6
Number of subjects: 48
Study 30969910 — intervention group
Group type: COMPARATOR
Intervention: VA version of NU-6
Number of subjects: 48
Study 28472415 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure treatment (15 min, 4 times a week for 12 weeks)
Number of subjects: 100
Study 25576474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Number of subjects: 94
Study 25576474 — intervention group
Group type: COMPARATOR
Intervention: Lower-Limb Exercises
Number of subjects: 94
Study 23497934 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative non-invasive ventilation for 7 days at home
Number of subjects: 300
Study 23497934 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 300
Study 21525252 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet plus aerobic exercise (5 d · wk(‐1), 60 min · d(‐1), 80‐85% heart rate(max))
Number of subjects: 28
Study 21525252 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic index diet plus aerobic exercise (5 d · wk(‐1), 60 min · d(‐1), 80‐85% heart rate(max))
Number of subjects: 28
Study 19048237 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 7
Study 19048237 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 7
Study 19048237 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 7
Study 16954548 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 20
Study 15600379 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (SNRI)
Number of subjects: 0
Study 15600379 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs (fluoxetine, paroxetine, sertraline, citalopram)
Number of subjects: 0
Study 15600379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11327200 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine ER 4mg once daily
Number of subjects: 19
Study 11327200 — intervention group
Group type: COMPARATOR
Intervention: tolterodine IR 2mg twice daily
Number of subjects: 19
Study 9387134 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protein load (2 g/kg of protein as beefsteak)
Number of subjects: 21
Study 9387134 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance
Number of subjects: 21
Study 9387134 — intervention group
Group type: COMPARATOR
Intervention: Group A (GFR 112 +/- 3 ml/min x 1.73 m2)
Number of subjects: 21
Study 9387134 — intervention group
Group type: COMPARATOR
Intervention: Group B (GFR 68 +/- 3.2 ml/min x 1.73 m2)
Number of subjects: 21
Study 9387134 — intervention group
Group type: COMPARATOR
Intervention: Group C (GFR 40.7 +/- 3.3 ml/min x 1.73 m2)
Number of subjects: 21
Study 7968283 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of ferric ammonium citrate
Number of subjects: 174
Study 7968283 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg of ferric ammonium citrate
Number of subjects: 174
Study 7968283 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of parasympathetic blockers
Number of subjects: 174
Study 7968283 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with fasting
Number of subjects: 174
Study 2737270 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms budesonide
Number of subjects: 0
Study 2737270 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms budesonide
Number of subjects: 0
Study 2737270 — intervention group
Group type: COMPARATOR
Intervention: 5 mg prednisolone
Number of subjects: 0
Study 2737270 — intervention group
Group type: COMPARATOR
Intervention: 10 mg prednisolone
Number of subjects: 0
Study 1174258 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified milk formula
Number of subjects: 0
Study 1174258 — intervention group
Group type: COMPARATOR
Intervention: Artificial milk formula (not iron-fortified)
Number of subjects: 0
Study 31573611 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-casein complex
Number of subjects: 21
Study 31573611 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate (control)
Number of subjects: 21
Study 28492342 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-level positive mental well-being and health behaviours
Number of subjects: 40
Study 28492342 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-level social networks
Number of subjects: 40
Study 28492342 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighbourhood-level measures of social networks and perceived neighbourhood quality
Number of subjects: 40
Study 28492342 — intervention group
Group type: EXPERIMENTAL
Intervention: Differences at the neighbourhood level
Number of subjects: 40
Study 25310464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling (LIFE)
Number of subjects: 113
Study 25310464 — intervention group
Group type: COMPARATOR
Intervention: Reference group (REF)
Number of subjects: 113
Study 24298767 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 40
Study 24298767 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture + Acupoint Injection (EA + AI)
Number of subjects: 40
Study 22649136 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose involved-field radiation therapy (IFRT)
Number of subjects: 498
Study 22649136 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (control)
Number of subjects: 498
Study 19787180 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical activity during Ramadan
Number of subjects: 93
Study 19787180 — intervention group
Group type: COMPARATOR
Intervention: No regular physical activity during Ramadan
Number of subjects: 93
Study 17092974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 16
Study 17092974 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg)
Number of subjects: 16
Study 17092974 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg)
Number of subjects: 16
Study 17092974 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2.5 mg)
Number of subjects: 16
Study 17092974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15302283 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (1:1 ratio of human-derived FSH:hMG)
Number of subjects: 0
Study 15302283 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (3:0 ratio changed to 1:1 after GS day 5)
Number of subjects: 0
Study 15302283 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (2:1 ratio increased to 3:1, 4:1, or 5:1 after GS day 5)
Number of subjects: 0
Study 15302283 — intervention group
Group type: EXPERIMENTAL
Intervention: Women <34 years
Number of subjects: 0
Study 15302283 — intervention group
Group type: EXPERIMENTAL
Intervention: Women 34 to 40 years
Number of subjects: 0
Study 11263519 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual reintroduction of isoniazid, rifampicin, ethambutol and streptomycin (Group I, n = 20)
Number of subjects: 45
Study 11263519 — intervention group
Group type: COMPARATOR
Intervention: Full-dose regimen of isoniazid, rifampicin, pyrazinamide and ethambutol (Group II, n = 25)
Number of subjects: 45
Study 9740450 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified PVP-free ICSI procedure
Number of subjects: 20
Study 9740450 — intervention group
Group type: COMPARATOR
Intervention: Conventional ICSI using polyvinylpyrrolidone (PVP)
Number of subjects: 20
Study 9740450 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (Modified ICSI and Conventional ICSI)
Number of subjects: 20
Study 8027221 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg YM175
Number of subjects: 79
Study 8027221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of YM175
Number of subjects: 79
Study 2838715 — intervention group
Group type: EXPERIMENTAL
Intervention: 113mIn-indifor
Number of subjects: 88
Study 2838715 — intervention group
Group type: COMPARATOR
Intervention: 99m Tc-phosphates
Number of subjects: 88